安科生物
(300009)
| 流通市值：126.08亿 | | | 总市值：172.60亿 |
| 流通股本：12.22亿 | | | 总股本：16.73亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,962,590,112.69 | 1,292,187,881.95 | 628,754,570.48 | 2,536,042,781.68 |
| 营业收入 | 1,962,590,112.69 | 1,292,187,881.95 | 628,754,570.48 | 2,536,042,781.68 |
| 二、营业总成本 | 1,345,964,715.95 | 885,306,876.29 | 394,534,887.63 | 1,780,935,163.99 |
| 营业成本 | 471,560,303.44 | 304,328,562.42 | 144,887,005.33 | 573,308,673.39 |
| 税金及附加 | 15,976,758.03 | 10,818,890.74 | 5,498,189.7 | 21,351,075.98 |
| 销售费用 | 597,938,935.41 | 395,373,392.28 | 171,303,320.18 | 819,380,286.48 |
| 管理费用 | 112,101,894.95 | 76,117,501.31 | 36,515,762.1 | 167,248,514.77 |
| 研发费用 | 145,384,774.02 | 95,820,124.67 | 33,910,492.09 | 201,286,759.72 |
| 财务费用 | 3,002,050.1 | 2,848,404.87 | 2,420,118.23 | -1,640,146.35 |
| 其中:利息费用 | 1,674,560.52 | 1,162,065.62 | 570,651.19 | 2,404,671.12 |
| 其中:利息收入 | 2,612,900.96 | 1,805,832.05 | 919,845.28 | 4,985,499.52 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,771,625.65 | -986,558.98 | -979,808.74 | 10,518,654.06 |
| 加:投资收益 | 11,267,643.47 | 11,188,455.65 | 6,347,951.75 | 15,434,956.87 |
| 资产处置收益 | 676,184.15 | 520,388.61 | 229,899.18 | 1,089,285.1 |
| 资产减值损失(新) | -3,820,281.73 | -3,099,669.73 | 0 | -7,850,983.9 |
| 信用减值损失(新) | -976,532.7 | -1,002,141.61 | -3,321,652.67 | -8,964,284.53 |
| 其他收益 | 23,956,711.18 | 18,829,280.91 | 11,470,548.23 | 41,061,568.17 |
| 四、营业利润 | 649,500,746.76 | 432,330,760.51 | 247,966,620.6 | 806,396,813.46 |
| 加:营业外收入 | 4,018.25 | 5,353.8 | -26,694.69 | 1,003,079.59 |
| 减:营业外支出 | 820,515.07 | 255,092.39 | 77,019.65 | 4,383,190.13 |
| 五、利润总额 | 648,684,249.94 | 432,081,021.92 | 247,862,906.26 | 803,016,702.92 |
| 减:所得税费用 | 86,062,811.87 | 57,527,406.54 | 34,547,937.89 | 87,178,796.76 |
| 六、净利润 | 562,621,438.07 | 374,553,615.38 | 213,314,968.37 | 715,837,906.16 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 562,621,438.07 | 374,553,615.38 | 213,314,968.37 | 715,837,906.16 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 551,483,266.04 | 366,517,170.34 | 209,002,473.85 | 706,948,363.86 |
| 少数股东损益 | 11,138,172.03 | 8,036,445.04 | 4,312,494.52 | 8,889,542.3 |
| 扣除非经常损益后的净利润 | 518,981,844.93 | 341,883,418.97 | 196,897,971.61 | 647,051,033.73 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.33 | 0.22 | 0.12 | 0.42 |
| (二)稀释每股收益 | 0.33 | 0.22 | 0.12 | 0.42 |
| 八、其他综合收益 | -78,746,995.87 | -71,008,287.24 | -44,881,085.5 | - |
| 归属于母公司股东的其他综合收益 | -78,746,995.87 | -71,008,287.24 | -44,881,085.5 | - |
| 九、综合收益总额 | 483,874,442.2 | 303,545,328.14 | 168,433,882.87 | 715,837,906.16 |
| 归属于母公司股东的综合收益总额 | 472,736,270.17 | 295,508,883.1 | 164,121,388.35 | 706,948,363.86 |
| 归属于少数股东的综合收益总额 | 11,138,172.03 | 8,036,445.04 | 4,312,494.52 | 8,889,542.3 |
| 公告日期 | 2025-10-28 | 2025-08-22 | 2025-04-29 | 2025-03-28 |
| 审计意见(境内) | | | | 标准无保留意见 |